- Home
- MSGS vs QGEN Comparison
MSGS vs QGEN Comparison
Compare MSGS & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MSGS | QGEN |
|---|---|---|
| Founded | 1879 | 1986 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.4B | 9.0B |
| IPO Year | 2015 | 1998 |
Fundamental Metrics
Financial Performance| Metric | MSGS | QGEN |
|---|---|---|
| Price | $384.39 | $50.22 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 7 | 12 |
| Target Price | ★ $493.80 | $49.20 |
| AVG Volume (30 Days) | 338.4K | ★ 4.5M |
| Earning Date | 11-10-2026 | 11-04-2026 |
| Dividend Yield | N/A | ★ 5.48% |
| EPS Growth | ★ 134.41 | N/A |
| EPS | ★ 0.32 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $2.18 |
| Revenue Next Year | $3.74 | $5.00 |
| P/E Ratio | $1,204.17 | ★ $24.01 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $207.90 | $32.53 |
| 52 Week High | $438.93 | $57.82 |
Technical Indicators
Market Signals| Indicator | MSGS | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 40.01 | 72.64 |
| Support Level | $379.80 | $49.37 |
| Resistance Level | $407.02 | $50.34 |
| Average True Range (ATR) | 12.38 | 1.14 |
| MACD | -2.18 | 0.44 |
| Stochastic Oscillator | 6.43 | 91.91 |
Price Performance
Historical ComparisonAbout MSGS Madison Square Garden Sports Corp. (New)
Madison Square Garden Sports Corp is owns and operates a portfolio of assets featuring some of the recognized teams in all of sports, including the Knicks of the National Basketball Association (NBA) and the Rangers of the National Hockey League (NHL). The company has one operating and reportable segment.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables, with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by Europe, the Middle East, and Africa (33%) and Asia-Pacific (15%).